COCCO, CLAUDIO
 Distribuzione geografica
Continente #
NA - Nord America 399
EU - Europa 294
AS - Asia 97
Totale 790
Nazione #
US - Stati Uniti d'America 396
GB - Regno Unito 133
CN - Cina 86
SE - Svezia 53
FR - Francia 29
IE - Irlanda 25
DE - Germania 16
FI - Finlandia 14
IT - Italia 10
KR - Corea 8
UA - Ucraina 7
BE - Belgio 3
CA - Canada 3
AT - Austria 1
CH - Svizzera 1
IN - India 1
JP - Giappone 1
NL - Olanda 1
RU - Federazione Russa 1
TR - Turchia 1
Totale 790
Città #
Southend 108
Chandler 83
Jacksonville 56
Houston 47
Ann Arbor 35
Dublin 25
Woodbridge 25
Ashburn 23
Beijing 16
Lancaster 12
Lawrence 11
Princeton 11
Nanjing 9
Wilmington 9
Jinan 8
Seoul 8
Hebei 7
Boardman 6
Detroit 6
Nanchang 6
Jiaxing 5
Tianjin 5
Verona 5
New York 4
Taiyuan 4
Brussels 3
Cascia 3
Dearborn 3
Leipzig 3
Fuzhou 2
Guangzhou 2
Haikou 2
Hangzhou 2
Helsinki 2
Phoenix 2
Shenyang 2
Toronto 2
Zhengzhou 2
Auburn Hills 1
Bilgi 1
Buffalo 1
Calgary 1
Changsha 1
Chaoyang 1
Clearwater 1
Cuddalore 1
Edinburgh 1
Fairfield 1
Falkenstein 1
Fushan 1
Kemerovo 1
Lanzhou 1
Los Angeles 1
Riva 1
San Francisco 1
Seattle 1
Taizhou 1
Tokyo 1
Vienna 1
Washington 1
Zurich 1
Totale 587
Nome #
Follicle-Stimulating Hormone and the Pituitary-Testicular-Prostate Axis at the Time of Initial Diagnosis of Prostate Cancer and Subsequent Cluster Selection of the Patient Population Undergoing Standard Radical Prostatectomy 98
Is it possible to use the identification of neutrophil gelatinase- associated lipocalin (NGAL) in the evaluation of bisphosphonates nephrotoxicity? [E' possibile utilizzare la determinazione della lipocalina associata alla gelatinasi dei neutrofili (NGAL) nella valutazione della nefrotossicità da bisfosfonati?] 90
Investigative clinical study on prostate cancer part VIII: prolactin hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy. 82
Investigative clinical study on prostate cancer Part V: Luteinizing hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population. 79
Investigative clinical study on prostate cancer part VI: Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population. 75
Investigative clinical study on prostate cancer part VII: prolactin and the pituitary-testis-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population. 69
DEFINITION OF UPPER REFERENCE LIMIT FOR THYROID PEROXIDASE AUTOANTIBODIES ACCORDING TO NACB GUIDELINES: COMPARISON OF SEVEN DIFFERENT AUTOMATED METHODS. Part B (in : Reference ranges, standardization and decision levels) 67
Investigative clinical study on prostate cancer part IX and X: estradiol and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy 66
DEFINITION OF UPPER REFERENCE LIMIT FOR THYROID PEROXIDASE AUTOANTIBODIES ACCORDING TO NACB GUIDELINES: COMPARISON OF FIVE DIFFERENT AUTOMATED METHODS. PART A (in Reference ranges, standardization and decision levels) 62
Role of CA 15-3 to guide therapy in metastatic breast cancer [Il ruolo di CA 15-3 nel monitoraggio della terapia nel carcinoma mammario metastatico] 60
Choosing wisely: la lista del gruppo di studio Endocrinologia e Malattie del Metabolismo della Società Italiana di Patologia Clinica e Medicina di Laboratorio 55
Totale 803
Categoria #
all - tutte 2.568
article - articoli 2.091
book - libri 0
conference - conferenze 477
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.136


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201915 0 0 0 0 0 0 0 0 0 0 6 9
2019/202088 13 0 0 7 7 11 21 4 3 7 6 9
2020/202172 3 17 7 9 6 10 2 5 0 1 9 3
2021/2022118 12 36 0 23 0 7 2 6 2 2 4 24
2022/2023196 20 17 23 26 20 41 3 17 16 1 8 4
2023/202482 4 14 9 5 16 15 1 7 0 11 0 0
Totale 803